Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.
3 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cantor Fitzgerald provided ratings and price targets for EyePoint Pharmaceuticals.1 source
EyePoint Pharmaceuticals is listed on Nasdaq and is currently receiving analyst research reports.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
-
Nasdaq
American fully electronic stock exchange
Related events
- MarketBeat reported analyst recommendations for AMCI Acquisition Corp., which is listed on the Nasdaq electronic stock exchange.
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
- Affirm listed on the Nasdaq stock exchange, filed disclosures with the SEC, and received research reports from Needham & Company.
- Information was published regarding X-Energy's company performance, which is traded on the Nasdaq stock exchange.
- Versant was listed on the electronic stock exchange and received analyst recommendations from MarketBeat.